Though many corporate laboratories claim to staff ‘GI pathologists,’ gastroenterology is still not a recognized subspecialty by the American Board of Pathology. Our physicians have been interpreting a wide range of gastrointestinal biopsies from ambulatory and hospitalized patients for decades. This experience, combined with the close working relationship we maintain with many of our clients, has given us specialized expertise in the interpretation of routine and challenging GI cases from both children and adults in the community.
In order to provide the highest quality diagnostic GI service:
All new diagnoses of idiopathic inflammatory bowel disease (IIBD) and malignancy are routinely reviewed at our daily consensus conference, as are other unusual or borderline cases.
Preliminary diagnoses on stat cases are available by 9 am the next day.
All diagnoses of malignancy are verbally reported and confirmed.
We are always available for direct consultation regarding clinical-pathologic correlation.
For patients with a diagnosis of malignancy, we offer:
Mismatch repair (MMR) protein analysis for the detection of MSI-related adenocarcinomas. Patients with defective MMR protein expression have a greater probability of suffering from an inherited syndrome that increases their risk of cancer, and these patients and their families may benefit from subsequent targeted mutational analysis to confirm a hereditary syndrome.
HER2 immunohistochemistry and FISH for adenocarcimomas of the gastroesophageal junction and stomach.
To help you manage your practice we provide:
Adenoma Detection Rates (ADR) for all endoscopists.
A quarterly summary of your biopsy volume and diagnoses, by anatomic location.
A comparison of your practice patterns with the de-identified aggregate data of other endoscopists.